login
login

Europe Daily Bulletin No. 8884

9 February 2005
Contents Publication in full By article 42 / 49
ECONOMIC INTERPENETRATION / (eu) pharmacy

The Swiss laboratory NOVARTIS is looking to buy some or all of the activities of HEXAL, the German number two in the production of generic medicines. NOVARTIS is said to be prepared to pay between 2.5 and 3 billion EUR. HEXAL's turnover was 1.35 billion EUR in 2004 and employs 7400. It sells over 250 products.

Contents

A LOOK BEHIND THE NEWS
THE DAY IN POLITICS
GENERAL NEWS
ECONOMIC INTERPENETRATION